Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.

One aspect of the present invention is directed to a method for detecting acute Borna Disease Virus (BDV) infections. According to the invention, the presence of heterodimers of p24 BDV phosphoprotein and p40 BDV nucleoprotein in a sample is determined by means of antibodies of both proteins using a sandwich ELISA. The invention also relates to a diagnostic kit for a sandwich ELISA for detecting mute BDV infections. Said kit uses a antibody of p24 BDV phosphoprotein and a second primary antibody of p40 BDV nucleoprotein, at least one reporter-molecule-labelled secondary antibody, means for immobilising a primary antibody on a surface, and instructions for carrying out the method according to the invention. The invention also relates to the combination of the method according to the invention and the new diagnostic kit with known methods for detecting circulating immune complexes (CIC) and antibodies. Acute BDV infections are thus distinguished from chronic and latent ones (humans and animals), allowing, for example, differential diagnosis and treatment monitoring for diseased individuals but also the identification of health risks depending on infection status in healthy carriers.

The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.

Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.

Polyclonal Antibodies produced using HIV-1 Trimeric Envelope Glycoprotein Subunits (TEGS) are provided. TEGS are comprised of non-infectious complexes comprising a trimeric envelope glycoprotein subunit comprising gp120 bound to membrane-anchored trimeric native gp41. The gp120 and gp41 present in the TEGS are not chemically fixed or cross-linked. Immunization with the TEGS elicits polyclonal antibodies that neutralize diverse viruses in HIV infection assay using peripheral blood mononuclear cells (PBMCs). The present invention relates to a method for reducing the occurrence and/or severity of HIV infections.

A single stranded nucleic acid aptamer able to specifically bind to at least one Adenovirus type, the aptamer comprising or consisting of one of sequences SEQ ID NO:1 to 3, or variants thereof having at least 50% sequence identity. Additionally, a composition comprising the aptamer. Furthermore, use of the aptamer, for detecting, capturing, concentrating and/or quantifying at least one Adenovirus type. Still further, in vitro methods for capturing, detecting and/or quantifying at least one Adenovirus type. Further yet, a kit for detecting, quantifying, capturing and/or concentrating at least one Adenovirus type.

Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.

Disclosed herein are sensor systems, compositions comprising the sensor systems, and methods of using the same. In particular aspects, disclosed herein are sensor systems for a target intracellular ligand and uses thereof, e.g., in detection assays or in cell manipulation or therapeutic applications.

The present application relates to the field of biochip detection apparatus, and in particular to a fully automated biochip workstation and a detection method using same. Biochip detection apparatus comprises a cavity for carrying a test tube vial, the test tube vial being used for accommodating a sample to be detected and a biochip, the cavity having a temperature control function; a liquid storage device for storing liquid; a pumping device for pumping the liquid in the liquid storage device to the test tube vial, the pumping device being in fluid communication with a separation needle for injecting a mixed liquid into the test tube vial; an imaging device for monitoring the chip state in the test tube vial; and a data processing device configured to acquire hybridization results on the basis of information about a biochip state acquired by the imaging device. The biochip workstation provided in the present application implements the integration of biochip reactions and the output of detection results, improves the processing efficiency of samples, saves manpower, and has more stable and reliable results.

An apparatus includes a surface acoustic wave (SAW) sensor. The SAW sensor includes a piezoelectric substrate. The SAW sensor also includes first and second interdigitating transistors over the piezoelectric substrate. The first interdigitating transistor is configured to convert an input electrical signal into an acoustic wave. The second interdigitating transistor is configured to convert the acoustic wave into an output electrical signal. The piezoelectric substrate is configured to transport the acoustic wave. The SAW sensor further includes a detection layer over the piezoelectric substrate and positioned at least partially between the first and second interdigitating transistors. The detection layer includes (i) antibodies configured to bind to one or more biological analytes and (ii) a hydrogel layer over the antibodies.